Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group 2014 sales

Diagnostics

Foreign exchange rate information

Changes to the development pipeline *FY 2014 update*

New to Phase I	New to Phase II	New to Phase III	New to Registration
11 NMEs **RG6047** SERD (2) – ER-pos (HER2-neg) mBC **RG6078** IDO inh - solid tumors **RG7802** CEA CD3 TCB - solid tumors **RG7876** CD40 iMAb+PD-L1 MAb - solid tumors **RG7787** MSLN-PE cFP – solid tumors **RG7689** NME – infectious diseases **RG7880** NME - autoimmune diseases **RG7625** NME - autoimmune diseases **RG6080** DBO β-lactamase inh - bacterial infections **RG7345** TAU pS422 MAb – AD **RG7597** HER3/EGFR DAF+cobimetinib – KRAS mutation-pos tumors **2AIs** **RG7155** CSF-1R+PD-L1 MAb - solid tumors **RG7446** PD-L1 MAb + Gazyva – lymphoma	**2NMEs transitioned from Ph1** **RG6046** SERD ER-pos (HER2-neg) mBC **CHU**: URAT 1 inh - gout **5 AIs** **RG3502** Kadcyla – HER2-pos advanced NSCLC **RG435** Avastin + Tarceva - EGFR mut-pos. NSCLC **RG6062** Esbriet – ILD, systemic sclerosis related **RG7421** cobimetinib – triple negative breast cancer **RG7601** venetoclax (Bcl-2-inh)+ Rituxan - rel/ref follicular lymphoma	**3 AIs** **RG7601** venetoclax (Bcl-2 inh)+ Gazyva - CLL 1st line **RG7446** PD-L1 bladder cancer 2nd line **CHU** Actemra – large-vessel vasculitis (added by Chugai)	**1 AI following EU submission** **RG105** MabThera – CLL subcutaneous formulation
Removed from Phase I	**Removed from Phase II**	**Removed from Phase III**	**Removed from Registration**
3 NMEs **RG7666** PI3K inh - glioblastoma 2L **RG7624** IL-17 MAb - autoimmune diseases **RG7458** MUC16 ADC - ovarian and pancreatic cancer	**6 NMEs** **RG7593** pinatuzumab vedotin (CD22 ADC) - heme tumors **RG7449** quilizumab - asthma **RG7128** mericitabine - HCV **RG1512** inclacumab - ACS/CVD **RG1578** decoglurant (mGluR2 NAM) - depression **RG7597** HER3/EGFR DAF m. epithelial tumors	**1 AI removed by Chugai** Suvenyl - enthesopathy	**1 AI following US approval** **RG435** Avastin - rel. ovarian ca. Pt-resistant

Status as of January 28, 2015

Roche Group development pipeline

Phase I
(33 NMEs + 11 AIs)

Oncology

RG6016	LSD1 inh	AML
RG6047	SERD (2)	ER+(HER2-neg) mBC
RG6061	HIF1 alpha LNA	solid tumors
RG6078	IDO inh	solid tumors
RG7116	HER3 MAb	solid tumors
RG7155	CSF-1R + PDL-1 MAb	solid tumors
RG7304	Raf & MEK dual inh	solid tumors
RG7388	MDM2 ant	solid & hem tumors
RG7446	PD-L1 MAb+Tarceva	NSCLC EGFR+
RG7446	PD-L1 MAb+Zelboraf+/-cobimetinib	m. melanoma
RG7446	PD-L1 MAb+Avastin+chemo	solid tumors
RG7446	PD-L1 MAb+cobimetinib	solid tumors
RG7446	PD-L1 MAb+ipi/IFN	solid tumors
RG7446	PD-L1 MAb	solid tumors
RG7446	PD-L1 MAb+Gazyva	lymphoma
RG7450	Steap 1 ADC	prostate ca.
RG7597	HER3/EGFR DAF+ cobi	KRAS+ s. tumors
RG7601	venetoclax (Bcl-2)+ Gazyva	CLL
RG7601	venetoclax (Bcl-2)	heme indications
RG7741	ChK1 inh	solid tum & lymphoma
RG7775	MDM2 (4) IV prodrug	AML
RG7787	MSLN PE cFP	solid tumors
RG7802	CEA CD3 TCB	solid tumors
RG7813	CEA IL2v	solid tumors
RG7841	ADC	solid tumors
RG7842	ERK inh	solid tumors
RG7876	CD40 iMAb+PD-L1 MAb	solid tumors
RG7882	ADC	ovarian ca
RG7888	OX40 MAb	solid tumors

Other disease areas

RG7625		autoimmune diseases
RG7880	-	autoimmune diseases
RG6080	DBO β-lactamase inh	bact. infections
RG7689	-	infectious diseases
RG7795	TLR7 agonist	HBV
RG7641	aldosterone synth inh	met. diseases
RG7203	PDE10A inh	schizophrenia
RG7342	mGlu5 PAM	schizophrenia
RG7345	TAUpS422 MAb	Alzheimer's
RG7410	TAAR1 ago	schizophrenia
RG7893	Nav1.7 inh	pain
RG7800	SMN2 splicer	spinal muscular atrophy
RG7935	a-synuclein MAb	Parkinson's Disease
RG3645	Lucentis sust. deliv.	AMD/RVO/DME
RG7716	VEGF-ANG2 MAb	wAMD

New Molecular Entity (NME)
Additional Indication (AI)

Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

RG-No **Roche Genentech managed**
CHU **Chugai managed**

Status as of January 28, 2015

Roche Group development pipeline

Phase II
(23 NMEs + 12 AIs)

RG435	Avastin+Tarceva	EGFR mut+ NSCLC
RG3502	Kadcyla	HER2+ NSCLC
RG6013	FIXa /FX bispecific MAb	hemophilia A
RG6046	SERD	ER+(HER2-neg) mBC
RG7155	CSF-1R MAb	PVNS/solid tumors
RG7221	Ang2-VEGF MAb	colorectal cancer
RG7321	pictilisib	solid tumors
RG7421	cobimetinib	TNBC
RG7440	ipatasertib (AKT inh)	solid tumors
RG7446	PD-L1 MAb	NSCLC 2nd/3rd line
RG7446	PD-L1 MAb + Avastin	RCC
RG7446	PD-L1 MAb	bladder cancer 1/2l
RG7596	polatuzumab vedotin (CD79bADC)	hem tumors
RG7599	lifastuzumab vedotin (NaPi2bADC)	Pt-resist. OC
RG7601	venetoclax (Bcl-2)	C LL rel/refract 17pdel
RG7601	venetoclax (Bcl-2)	DLBCL
RG7601	venetoclax (Bcl-2)+ Rituxan	rel/ref FL
RG7604	taselisib (mutant-selective)	solid tumors
RG7686	glypican-3 MAb	liver cancer
RG1569	Actemra	systemic sclerosis
RG3637	lebrikizumab	IPF
RG6062	Esbriet	SSc – interstitial lung disease
CHU	IL-31R MAb	atopic dermatitis
RG7227	danoprevir	HCV
RG7745	Flu A MAb	influenza
RG7790	setrobuvir	HCV
RG7929	LptD antibiotic	antibacterial
RG7697	GIP/GLP-1 dual ago	type 2 diabetes
CHU	URAT 1 inh	gout
RG1577	MAO-B inh	Alzheimer's
RG1662	GABRA5 NAM	Down Syndrome
RG1678	bitopertin	obsessive compulsive dis.
RG7090	basimglurant (mGlu5 NAM)	TRD
RG7314	V1 receptor antag	autism
RG7412	crenezumab	Alzheimer's

Phase III
(9 NMEs + 21 AIs)

RG435[1]	Avastin	glioblastoma 1st line
RG435[1]	Avastin	ovarian cancer 1st line
RG435[1]	Avastin	rel. ovarian ca. Pt-sensitive
RG435	Avastin	NSCLC adj
RG1273	Perjeta	HER2+ mBC 2nd line
RG1273	Perjeta	HER2+ BC adj
RG1273	Perjeta	HER2+ gastric cancer 1st line
RG3502	Kadcyla	HER2+ gastric cancer 2nd line
RG3502	Kadcyla +/- Perjeta	HER2+ mBC 1st l
RG3502	Kadcyla	HER2+ BC adj
RG3502	Kadcyla + Perjeta	HER2+ BC adj
RG3502	Kadcyla + Perjeta	HER2+ BC neoadj
RG7159	Gazyva	DLBCL 1st line
RG7159	Gazyva	iNHL rituximab refractory
RG7159	Gazyva	follicular lymphoma 1st line
RG7204	Zelboraf	melanoma adj
RG7446	PD-L1 MAb	NSCLC 2nd line
RG7446	PD-L1 MAb	bladder cancer 2nd line
RG7601	venetoclax (Bcl-2) + Rit.	CLL rel/ref
RG7601	venetoclax+Gazyva (Bcl-2)	CLL 1st line
RG7853	alectinib (ALK inhibitor)	NSCLC
RG1569	Actemra	giant cell arteritis
RG3637	lebrikizumab	severe asthma
RG7413	etrolizumab	ulcerative colitis
CHU	Actemra	large-vessel vasculitis
CHU	IL-6R MAb	neuromyelitis optica
RG1450	gantenerumab	Alzheimer's
RG1594	ocrelizumab	RMS
RG1594	ocrelizumab	PPMS
RG7417	lampalizumab (factor D)	geo. atrophy

Registration
(1 NME + 4 AIs)

RG105	MabThera SC	CLL
RG435[2]	Avastin	recurrent cervical cancer
RG1273[2]	Perjeta	HER2+ BC neoadj
RG7421	cobimetinib + Zelboraf	m. melanoma
RG3645[3]	Lucentis	diabetic retinopathy

1 US only : FDA submission decision pending
2 Approved in US, submitted in EU
3 Submitted in US

New Molecular Entity (NME)
Additional Indication (AI)

Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other

RG-No Roche Genentech managed
CHU Chugai managed
RG105 MabThera is branded as Rituxan in US and Japan
RG1569 Actemra is branded as RoActemra in EU
RG7159 Gazyva is branded as Gazyvaro in EU

Status as of January 28, 2015

NME submissions and their additional indications

Projects currently in phase 2 and 3



Unless stated otherwise, submissions are planned to occur in US and EU

* lead market China

Status as of January 28, 2015

Submissions of additional indications for existing products

Projects currently in phase 2 and 3



✓ Indicates submission to health authorities has occurred.
* approved in EU; ** approved in US
Unless stated otherwise, submissions are planned to occur in US and EU.

Oncology
Immunology
Infectious Diseases
CardioMetabolism
Neuroscience
Ophthalmology
Other
NME

Status as of January 28, 2015

Major granted and pending approvals 2014



Status as of January 28, 2015 * Newly acquired asset (Intermune)

Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group 2014 results

Diagnostics

Foreign exchange rate information

Avastin

Ovarian cancer clinical development programme

Indication	Front-line metastatic ovarian cancer	
Phase/study	**Phase III GOG-0218**	**Phase III ICON7**
# of patients	N=1,873	N=1,528
Design	▪ **ARM A:** Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent placebo followed by placebo alone for up to 22 cycles (15 months) ▪ **ARM B:** Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by placebo alone for up to 22 cycles (15 months) ▪ **ARM C:** Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by Avastin alone for up to 22 cycles (15 months)	▪ **ARM A:** Paclitaxel and carboplatin for 6 cycles ▪ **ARM B:** Paclitaxel and carboplatin plus concurrent Avastin for 6 cycles followed by Avastin alone for up to 18 cycles (12 months)
Avastin dose	▪ 15 mg/kg q3 weeks	▪ 7.5 mg/kg q3 weeks
Primary endpoint	▪ Progression-free survival	▪ Progression-free survival
Status	▪ Study met its primary endpoint in Q1 2010 ▪ Data presented at ASCO 2010 and 2011 ▪ Results: NEJM 2011 Dec 29;365(26):2484-96	▪ Study met its primary endpoint Q3 2010 ▪ Data presented at ESMO 2010 and ASCO 2011 ▪ Results: NEJM 2011 Dec 29;365(26):2473-83 ▪ OS data presented at ECC 2013
	▪ EMA approval granted Q4 2011 ▪ Re-evaluate FDA submission in 2015	

ASCO=American Society of Clinical Oncology; ESMO=European Society for Medical Oncology

Avastin

Ovarian cancer clinical development programme

Indication	Relapsed platinum-sensitive ovarian cancer	Relapsed platinum-resistant ovarian cancer
Phase/study	**Phase III OCEANS**	**Phase III AURELIA**
# of patients	N=484	N=361
Design	▪ **ARM A:** Carboplatin, gemcitabine, and concurrent placebo for 6-10 cycles, followed by placebo alone until disease progression ▪ **ARM B:** Carboplatin, gemcitabine, and concurrent Avastin for 6-10 cycles, followed by Avastin alone until disease progression.	▪ **ARM A:** Paclitaxel, topotecan or liposomal doxorubicin ▪ **ARM B:** Paclitaxel, topotecan or liposomal doxorubicin plus Avastin
Avastin dose	▪ 15 mg/kg q3 weeks	▪ 10 mg/kg q2 weeks or 15 mg/kg q3 weeks
Primary endpoint	▪ Progression-free survival	▪ Progression-free survival
Status	▪ Study met its primary endpoint Q1 2011 ▪ EMA approval granted Q4 2012 ▪ Final data presented at SGO 2014 ▪ Re-evaluate FDA submission in 2015	▪ Study met its primary endpoint Q2 2012 ▪ Data presented at ASCO 2012 ▪ Results published in JCO 2014 May 1;32(13):1309-16 ▪ EMA approval granted Q3 2014 ▪ FDA approval granted Q4 2014

ASCO=American Society of Clinical Oncology; SGO=Society of Gynecologic Oncology; JCO=Journal of Clinical Oncology

Avastin

Cervical and brain cancer clinical development programmes

Indication	Stage IVB, recurrent or persistent cervical cancer	Newly diagnosed glioblastoma
Phase/study	**Phase III** **GOG-240**	**Phase III** **AVAglio**
# of patients	N=452	N=920
Design	▪ **ARM A:** Paclitaxel, cisplatin ▪ **ARM B:** Paclitaxel, cisplatin plus Avastin ▪ **ARM C:** Paclitaxel, topotecan ▪ **ARM D:** Paclitaxel, topotecan plus Avastin	▪ **ARM A:** Concurrent radiation and temozolomide plus placebo; followed by maintenance TMZ plus placebo for 6 cycles; then placebo until disease progression ▪ **ARM B:** Concurrent radiation and TMZ plus Avastin; followed by maintenance TMZ plus Avastin for 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression
Avastin dose	▪ 15 mg/kg q3 weeks	▪ 10 mg/kg q2 weeks or 15 mg/kg q3 weeks
Primary endpoint	▪ Overall survival	▪ Progression-free survival ▪ Overall survival
Status	▪ Study met its primary endpoint Q1 2013 ▪ Results published in NEJM Feb. 2014; 370(8):734-43 ▪ Filed globally Q2 2014 ▪ FDA approval granted Q3 2014	▪ Co-primary endpoint of PFS met Q3 2012 ▪ Overall survival data presented at ASCO 2013 ▪ Filed in EU Q1 2013 ▪ Negative CHMP opinion Q3 2014 ▪ US filing pending

TMZ=temozolomide
ASCO=American Society of Clinical Oncology

Avastin

Lung and breast cancer development programmes

Indication	Adjuvant lung cancer	First-line HER2-negative metastatic breast cancer
Phase/study	**Phase III ECOG 1505**	**Phase III MERiDiAN**
# of patients	N=1,500	N=480
Design	▪ **ARM A:** Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed ▪ **ARM B:** Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed plus Avastin up to 12 months	▪ **ARM A:** Paclitaxel + Avastin ▪ **ARM B:** Paclitaxel + Placebo
Avastin dose	▪ 15 mg/kg q3 weeks	▪ 10 mg/kg q2 weeks
Primary endpoint	▪ Overall survival	▪ PFS in ITT ▪ PFS in patients with high plasma VEGF-A
Status	▪ Recruitment completed Q4 2013 ▪ Expect data in 2016	▪ Recruitment completed ▪ Expect data in 2015

Erivedge

A novel small molecule inhibitor of the hedgehog signaling pathway

Indication	Locally advanced or metastatic basal cell carcinoma	Idiopathic pulmonary fibrosis
Phase/study	**Phase II STEVIE**	**Phase II**
# of patients	N=1,200	N=129
Design	▪ **Single ARM:** 150 mg Erivedge orally once daily	▪ **ARM A**: Erivedge 150mg daily ▪ **ARM B**: placebo
Primary endpoint	▪ Safety: Incidence of adverse events	▪ Change in forced vital capacity (FVC)
Status	▪ FPI Q2 2011	▪ FPI pending in anticipation of trial design amendment to incorporate new standard of care pirfenidone.

In collaboration with Curis

Esbriet

Small molecule with activity in fibrotic diseases

Indication	Systemic sclerosis-related interstitial lung disease (SSc-ILD)
Phase/study	**Phase II** **LOTUSS**
# of patients	N=63
Design	▪ Open-label, randomized, parallel-group, safety and tolerability study 2 week vs. 4 week dose titration regimens
Primary endpoint	▪ Safety
Status	▪ LPI Q3 2014 ▪ Data to be presented in 2015

In collaboration with Curis

Gazyva/Gazyvaro

Type II, glycoengineered anti-CD20 monoclonal antibody

Indication	Previously untreated or relapsed/refractory chronic lymphocytic leukemia	Diffuse large B-cell lymphoma (DLBCL)
Phase/study	**Phase III GREEN**	**Phase III GOYA**
# of patients	N=800	N=1,418
Design	▪ Single-arm cohort study: Gazyva alone or in combination with different chemotherapy regimens (FC, Bendamustin or Clb), investigation of different strategies to reduce IRRs	▪ **ARM A:** Gazyva 1000mg IV plus CHOP ▪ **ARM B:** MabThera/Rituxan plus CHOP
Primary endpoint	▪ Safety in combination with different chemotherapy regimens	▪ Progression-free survival
Status	▪ FPI Q4 2013 ▪ Initial safety data presented at ASH 2014	▪ Recruitment completed Q2 2014 ▪ Expect data in 2015

In collaboration with Biogen Idec
ASH=American Society of Hematology

Gazyva/Gazyvaro

Type II, glycoengineered anti-CD20 monoclonal antibody

Indication	Indolent non-Hodgkin's lymphoma MabThera/Rituxan refractory	Front-line indolent non-Hodgkin's lymphoma
Phase/study	**Phase III** **GADOLIN** Induction and maintenance study	**Phase III** **GALLIUM** Induction and maintenance study
# of patients	N=411	N=1,401
Design	▪ **ARM A:** Gazyva 1000mg iIV plus bendamustine followed by Gazyva mainteinance ▪ **ARM B:** bendamustine	▪ **ARM A:** Gazyva 1000mg IV plus chemotherapy followed by Gazyva maintenance ▪ **ARM B:** MabThera/Rituxan plus chemotherapy followed by MabThera/Rituxan maintenance ▪ Chemotherapy: ▪ For follicular lymphoma: CHOP, CVP or bendamustine ▪ For non-follicular lymphoma: physician's choice
Primary endpoint	▪ Progression-free survival	▪ Progression-free survival
Status	▪ LPI Q4 2014 ▪ Expect data in 2017	▪ Recruitment completed ▪ Expect data in 2017

In collaboration with Biogen Idec

CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, Vincristine and Prednisolone

Kadcyla

Evaluating new treatment options in HER2-positive early breast cancer

Indication	HER2-positive neoadjuvant breast cancer	HER2-positive early breast cancer high-risk patients	Operable HER2-positive early breast cancer
Phase/study	**Phase III KRISTINE**	**Phase III KATHERINE**	**Phase III KAITLIN**
# of patients	N=432	N=1,484	N=2,500
Design	Before surgery patients will receive 6 cycles of: ▪ **ARM A:** Herceptin plus Perjeta plus docetaxel plus carboplatin ▪ **ARM B:** Kadcyla plus Perjeta After surgery patients will receive: ▪ **ARM A:** Herceptin plus Perjeta ▪ **ARM B:** Kadcyla plus Perjeta	▪ **ARM A:** Kadcyla 3.6mg/kg q3w ▪ **ARM B:** Herceptin	▪ Following surgery and antracycline-based therapy: ▪ **ARM A:** Herceptin 6mg/kg q3w plus Perjeta 420 mg/kg q3w plus taxane ▪ **ARM B:** Kadcyla 3.6mg/kg q3w plus Perjeta 420mg/kg q3w
Primary endpoint	▪ Pathologic Complete Response (pCR)	▪ Invasive disease-free survival (IDFS)	▪ Invasive disease-free survival (IDFS)
Status	▪ FPI Q2 2014	▪ FPI Q1 2013	▪ FPI Q1 2014

In collaboration with ImmunoGen, Inc.

Kadcyla

Evaluating new treatment options in HER2-positive breast and gastric cancer

Indication	Previously untreated HER2 pos. metastatic breast cancer	Previously treated locally advanced or metastatic HER2-positive gastric cancer	HER2-positive advanced (2L+) NSCLC
Phase/study	**Phase III MARIANNE**	**Phase II/III GATSBY**	**Phase II**
# of patients	N=1,092	N=412	N=40
Design	▪ **ARM A:** Herceptin plus taxane ▪ **ARM B:** Kadcyla 3.6mg/kg q3w plus Perjeta ▪ **ARM C:** Kadcyla 3.6 mg/kg q3w plus placebo	▪ **ARM A**: Kadcyla 3.6mg/kg q3w ▪ **ARM B**: Kadcyla 2.4mg/kg weekly ▪ **ARM C**: docetaxel or paclitaxel	▪ Single-agent Kadcyla 3.6 mg/kg
Primary endpoint	▪ Progression-free survival assessed by IRF	▪ Phase II: Dose-finding ▪ Phase III: Overall survival	▪ Overall response rate and safety
Status	▪ Recruitment completed Q2 2012 ▪ Study met non-inferiority endpoint, showing similar progression-free survival (PFS) among the three arms Q4 2014 ▪ Study did not meet PFS superiority endpoint for Kadcyla-containing regimens Q4 2014	▪ FPI Q3 2012	▪ FPI Q4 2014

In collaboration with ImmunoGen, Inc.

MabThera/Rituxan

Oncology development programme

Indication	Previously untreated chronic lymphocytic leukemia
Phase/study	**Phase Ib** **SAWYER** Subcutaneous study *Study being conducted ex-US*
# of patients	N=225
Design	▪ Two-stage design: - Stage 1 (dose-finding, N=55) - Stage 2 (N=170): CLL dose confirmation: ▪ **ARM A**: MabThera IV plus chemotherapy (fludarabine and cyclophosphamide) ▪ **ARM B**: MabThera 1600mg SC plus chemotherapy (fludarabine and cyclophosphamide)
Primary endpoint	▪ Part 1: PK (dose selection) ▪ Part 2: PK of MabThera IV versus MabThera SC (arm A vs. arm B)
Status	▪ Stage 2 data confirmed non-inferior PK and comparable safety/efficacy of MabThera 1600mg SC vs. MabThera IV ▪ Presented at ASH 2014 ▪ Filed in EU Q4 2014

Subcutaneous MabThera : applies Enhanze technology, partnered with Halozyme
ASH=American Society of Hematology

Perjeta

First in a new class of HER dimerization inhibitors

Indication	Neoadjuvant HER2-positive breast cancer		Adjuvant HER2-positive breast cancer
Phase/ study	**Phase II NEOSPHERE**	**Phase II TRYPHAENA**	**Phase III APHINITY**
# of patients	N=417	N=225	N=4,803
Design	▪ **ARM A:** Herceptin plus docetaxel ▪ **ARM B:** Perjeta (840mg loading, 420mg q3w) plus Herceptin and docetaxel ▪ **ARM C:** Perjeta plus Herceptin ▪ **ARM D:** Perjeta plus docetaxel	▪ **ARM A:** FEC followed by Taxane with Herceptin and pertuzumab (H+P given concurrently) ▪ **ARM B:** FEC followed by Taxane with Herceptin + pertuzumab (H+P given sequentially) ▪ **ARM C:** TCH + pertuzumab (H+P given concurrently)	▪ **ARM A:** Perjeta (840mg loading, 420 q3w) plus Herceptin for 52 weeks plus chemotherapy (6-8 cycles) ▪ **ARM B**: placebo plus Herceptin (52 weeks) plus chemotherapy (6-8 cycles)
Primary endpoint	▪ Pathologic complete response (pCR)	▪ Safety	▪ Invasive disease-free survival (IDFS)
Status	▪ Positive data presented at SABCS 2010 ▪ Biomarker data presented SABCS 2011	▪ Positive safety and efficacy data presented at SABCS 2011	▪ Recruitment completed Q3 2013 ▪ Expect data in 2016
	▪ FDA approval granted Q3 2013 ▪ Filed in EU Q3 2014		

FEC = Fluorouracil, Epirubicin, and Cyclophosphamide; TCH = Docetaxel, Carboplatin, Herceptin; SABCS=San Antonio Breast Cancer Symposium.

Perjeta

First in a new class of HER dimerization inhibitors

Indication	Second-line HER2-positive metastatic breast cancer	Advanced HER2-positive gastric cancer	Neoadjuvant/adjuvant HER2-positive breast cancer
Phase/ study	**Phase III PHEREXA**	**Phase III JACOB**	**Phase II BERENICE**
# of patients	N=450	N=780	N=400
Design	▪ **ARM A:** Herceptin plus Xeloda ▪ **ARM B:** Perjeta plus Herceptin and Xeloda	▪ **ARM A:** Perjeta (840mg loading, 420mg q3w) plus Herceptin and chemotherapy ▪ **ARM B:** placebo plus Herceptin and chemotherapy	Neoadjuvant treatment: ▪ **ARM A:** ddAC q2w x4 cycles followed by weekly paclitaxel for 12 weeks, with P+H x4 cycles ▪ **ARM B:** FEC+P+H x4 cycles followed by docetaxel+P+H x4 cycles Adjuvant treatment: ▪ P+H q3w to complete 1 year of HER2 therapy ▪ Hormonal and radiation therapy as indicated
Primary endpoint	▪ Progression-free survival	▪ Overall survival	▪ Safety
Status	▪ Recruitment completed Q3 2013 ▪ Expect data in 2015	▪ FPI Q2 2013	▪ FPI Q3 2014

ddAC=dose-dense doxorubicin plus cyclophosphamide; FEC = Fluorouracil, Epirubicin, and Cyclophosphamide

Zelboraf

A selective novel small molecule that inhibits mutant BRAF

Indication	Adjuvant therapy in patients with resected cutaneous BRAF mutation positive melanoma
Phase/study	**Phase III** **BRIM8**
# of patients	N=725
Design	▪ 52-week treatment ▪ **ARM A:** Zelboraf 960mg bid ▪ **ARM B:** Placebo
Primary endpoint	▪ Disease-free survival
Status	▪ FPI Q3 2012

In collaboration with Plexxikon, a member of Daiichi Sankyo Group
See also combinations with: cobimetinib (MEK inhibitor) and anti-PDL1 (RG7446)

Actemra/RoActemra

Interleukin 6 receptor inhibitor

Indication	Systemic sclerosis	Giant Cell Arteritis
Phase/study	**Phase II** **faSScinate** Proof-of-concept study	**Phase III** **GiACTA**
# of patients	N=86	N=250
Design	▪ Blinded 48-week treatment with weekly dosing: ▪ **ARM A:** Actemra SC 162mg ▪ **ARM B:** Placebo SC Open-label weekly dosing at weeks 49 to 96: ▪ Actemra SC 162mg	▪ Part 1: 52-week blinded period ▪ **ARM A:** Actemra SC 162mg qw + 26 weeks prednisone taper ▪ **ARM B:** Actemra SC 162mg q2w + 26 weeks prednisone taper ▪ **ARM C:** Placebo+ 26 weeks prednisone taper ▪ **ARM D:** Placebo+ 52 weeks prednisone taper ▪ Part II: ▪ 104-week open label extension – patients in remission followed off of the study drug; Patients with active disease receive open label Actemra SC 162mg qw
Primary endpoint	▪ Change in modified Rodnan skin score (mRSS) at week 24 ▪ Safety	▪ Proportion of patients in sustained remission at week 52
Status	▪ 48 week data presented at ACR 2014 ▪ Primary and all key secondary endpoints showed trend for improved efficacy	▪ FPI Q3 2013

In collaboration with Chugai
ACR=American College of Rheumatology

Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group 2014 results

Diagnostics

Foreign exchange rate information

Alectinib (ALK inhibitor, RG7853, AF802)

New CNS-active inhibitor of anaplastic lymphoma kinase

Indication	ALK-positive crizotinib-naïve advanced NSCLC	ALK-positive advanced NSCLC after progression on crizotinib treatment	ALK-positive advanced NSCLC after progression on crizotinib treatment	Treatment naïve ALK-positive advanced NSCLC
Phase/study	**Phase I/II** **AF-001JP** Japanese study	**Phase I/II** **AF-002JG/NP28761** US study	**Phase I/II** **ACCALIA/NP28673**	**Phase III** **ALEX**
# of patients	N=70	Phase I: N=36 Phase II: N=85	N=130	N=286
Design	▪ **Part 1**: Dose escalation monotherapy ▪ **Part 2**: Monotherapy, dose selected based on the results of Part 1	▪ **Part 1**: Dose escalation monotherapy ▪ **Part 2**: Monotherapy, dose selected based on the results of Part 1	▪ **Part 1**: Dose escalation monotherapy ▪ **Part 2**: Monotherapy, dose selected based on the results of Part 1	▪ **ARM A**: alectinib 600mg BID ▪ **ARM A**: crizotinib 250mg BID
Primary endpoint	▪ Phase I: Determination of recommended dose ▪ Phase II: Safety and efficacy	▪ Phase I: Determination of recommended dose ▪ Phase II: Safety and efficacy	▪ Phase I: Determination of recommended dose ▪ Phase II: Safety and efficacy	▪ Progression-free survival
Status	▪ Results published in Lancet Oncology 2013 Jun;14(7):590-8 ▪ Approved in Japan with brand name ALECENSA July 2014	▪ Phase I data presented at ECC 2013 ▪ Phase I full cohort including CNS data published in Lancet Oncology 2014, Sept.15(10):1119-28 ▪ Phase II FPI Q3 2013	▪ Phase II FPI Q3 2013	▪ FPI Q3 2014
	▪ Breakthrough therapy designation granted by the FDA June 2013			

In collaboration with Chugai
ECC=European Cancer Congress

Anti-PDL1 (MPDL3280A, RG7446)

Novel approach in cancer immunotherapy

Indication	Metastatic NSCLC 2nd line	Locally advanced or metastatic NSCLC PD-L1 positive	Locally advanced or metastatic NSCLC PD-L1 positive	Locally advanced or metastatic NSCLC (2nd/3rd line)	Non-small cell lung cancer
Phase/study	**Phase III OAK**	**Phase II FIR**	**Phase II BIRCH**	**Phase II POPLAR**	**Phase I**
# of patients	N=1100	N=130	N=635	N=287	N=32
Design	▪ RG7446 1200mg q3w ▪ docetaxel	▪ Single arm study ▪ RG7446 1200mg q3w	▪ Single arm study ▪ RG7446 1200mg q3w	▪ **ARM A**: RG7446 1200mg q3w ▪ **ARM B**: Docetaxel	▪ RG7446 plus Tarceva[1]
Primary endpoint	▪ Overall survival	▪ Overall response rate	▪ Objective response rate	▪ Overall survival	▪ Safety
Status	▪ FPI Q1 2014	▪ Recruitment completed Q2 2014	▪ Recruitment completed Q4 2014	▪ Recruitment completed Q2 2014	▪ FPI Q1 2014

[1]Tarceva is a registered trademark of OSI Pharmaceuticals, LLC, a subsidiary of Astellas US, LLC;

Anti-PDL1 (MPDL3280A, RG7446)

Novel approach in cancer immunotherapy

Indication	Locally advanced or metastatic urothelial bladder cancer	Locally advanced or metastatic urothelial bladder cancer	Untreated advanced renal cell carcinoma
Phase/study	**Phase III**	**Phase II**	**Phase II**
# of patients	N=767	N=330	N=150
Design	Patients who progressed on at least one platinum-containing regimen will receive: ▪ **ARM A:** RG7446 1200mg q3w ▪ **ARM B:** chemotherapy (vinflunine, paclitaxel or docetaxel)	RG7446 1200mg q3w ▪ **Cohort 1**: Treatment-naive and cisplatin-ineligible patients ▪ **Cohort 2**: Patients with disease progression following or during platinum-containing treatment	▪ **ARM A**: RG7446 plus Avastin ▪ **ARM B**: RG7446; following PD: RG7446 plus Avastin ▪ **ARM C**: sunitinib; following PD: RG7446 plus Avastin
Primary endpoint	▪ Overall survival	▪ Objective response rate	▪ Progression free survival
Status	▪ FPI January 2015	▪ FPI Q2 2014	▪ FPI Q1 2014

Anti-PDL1 (MPDL3280A, RG7446)

Novel approach in cancer immunotherapy

Indication	Solid tumors	Solid tumors	Locally advanced or metastatic solid tumors	Relapsed/Refractory follicular lymphoma and DLBCL
Phase/study	**Phase I**	**Phase I**	**Phase I**	**Phase I**
# of patients	N=160	N=110	N=200	N=52
Design	▪ Part 1: sequential administration of RG7446 and RG7876 (CD40 iMAb) ▪ Part 2: concomitant administration of RG7446 and RG7876 ▪ Part 3: study drugs schedule in specific indication per Part 2	RG7446 in combination with RG7155 (anti-CSF1R) ▪ Part 1: dose escalation ▪ Part 2: expansion	▪ **ARM A:** RG7446 plus ipilimumab ▪ **ARM B:** RG7446 plus interferon alpha-2b	Stage 1: safety evaluation ▪ RG7446 plus Gazyva Stage 2: expansion ▪ RG7446 plus Gazyva
Primary endpoint	▪ Safety	▪ Safety	▪ Safety	▪ Safety
Status	▪ FPI Q4 2014	▪ FPI January 2015	▪ FPI Q3 2014	▪ FPI Q4 2014

Anti-PDL1 (MPDL3280A, RG7446)

Novel approach in cancer immunotherapy

Indication	Solid tumors	Previously untreated metastatic melanoma BRAF mutation positive	Locally advanced or metastatic tumors	Solid tumors
Phase/study	**Phase I**	**Phase I**	**Phase I**	**Phase I**
# of patients	N=180	N=44	N=90	N=344
Design	▪ **ARM A**: RG7446 + Avastin ▪ **ARM B**: RG7446 + Avastin + FOLFOX ▪ **ARM C**: RG7446 + Avastin + carboplatin+paclitaxel ▪ **ARM D**: RG7446 + Avastin + carboplatin+ pemetrexed ▪ **ARM E**: RG7446 + Avastin + carboplatin+ nab-paclitaxel	▪ Dose-finding study of RG7446 (anti-PDL1) + Zelboraf[1] and RG7446 (anti-PDL1) + Zelboraf[1] + cobimetinib combinations	▪ **ARM A:** Dose-finding – RG7446 plus cobimetinib[2] ▪ **ARM B:** Dose-expansion - RG7446 plus cobimetinib	▪ Dose escalation study
Primary endpoint	▪ Safety/PK	▪ Safety/PK	▪ Safety	▪ Safety/PK
Status	▪ FPI Q2 2012	▪ FPI Q4 2012	▪ FPI Q4 2013	▪ FPI Q2 2011 ▪ Initial efficacy data presented at ASCO 2013 ▪ Updated data presented at ECC 2013 ▪ Data from bladder cohort presented at ASCO and ESMO 2014

[1]Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group;
[2]Cobimetinib in collaboration with Exelixis

Cobimetinib (RG7421, GDC-0973)

Selective small molecule inhibitor of mitogen-activated protein kinase kinase

Indication	Previously untreated metastatic melanoma BRAF mutation positive	First-line metastatic triple negative breast cancer
Phase/study	**Phase III coBRIM**	**Phase II**
# of patients	N=495	N=112
Design	▪ **ARM A:** Zelboraf[1] plus cobimetinib ▪ **ARM B:** Zelboraf[1] plus placebo	▪ **ARM A:** cobimetinib plus paclitaxel ▪ **ARM B:** placebo plus paclitaxel
Primary endpoint	▪ Progression-free survival	▪ Progression-free survival, safety
Status	▪ Primary endpoint met Q3 2014 ▪ Data presented at ESMO and SMR 2014 ▪ Results published NEJM 2014 Nov 13;371(20):1867-76 ▪ Filed in EU Q3 2014 ▪ Filed in US Q4 2014	▪ FPI January 2015

In collaboration with Exelixis

[1]Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group;
ESMO=European Society for Medical Oncology; SMR=Society for Melanoma Research; NEJM=New England Journal of Medicine

Cobimetinib (RG7421, GDC-0973)

Selective small molecule inhibitor of mitogen-activated protein kinase kinase

Indication	Locally advanced or metastatic tumors	Previously untreated metastatic melanoma BRAF mutation positive	Locally advanced or metastatic tumors with mutant KRAS
Phase/study	**Phase I**	**Phase I**	**Phase I**
# of patients	N=90	N=44	N=50
Design	▪ **ARM A:** Dose-finding - cobimetinib plus RG7446 (anti-PDL1) ▪ **ARM B:** Dose-expansion - cobimetinib plus RG7446 (anti-PDL1)	▪ Dose-finding study of RG7446+Zelboraf[1] and RG7446+Zelboraf[1]+ cobimetinib combinations	▪ Dose finding of cobimetinib plus RG7597 (anti-HER3/EGFR DAF)
Primary endpoint	▪ Safety	▪ Safety/PK	▪ Safety
Status	▪ FPI Q4 2013	▪ FPI Q4 2012	▪ FPI Q4 2013

In collaboration with Exelixis

[1]Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group

Pictilisib (RG7321, GDC-0941)

Pan-PI3 kinase inhibitor with potential activity in multiple cancers

Indication	2L ER-positive metastatic breast cancer	Previously untreated advanced or recurrent NSCLC	Locally recurrent or metastatic HER2-negative HR-positive breast cancer
Phase	**Phase II** **FERGI**	**Phase II** **FIGARO**	**Phase II** **PEGGY**
# of patients	N=340	N=302	N=180
Design	▪ **ARM A:** pictilisib plus hormonal therapy ▪ **ARM B:** apitolisib plus hormonal therapy (ARM B discontinued) ▪ **ARM C:** Hormonal therapy + placebo	▪ **ARM A:** pictilisib + carboplatin + paclitaxel ▪ **ARM B:** placebo + carboplatin + paclitaxel ▪ **ARM C:** pictilisib+ carboplatin + paclitaxel + Avastin ▪ **ARM D:** placebo + carboplatin + paclitaxel + Avastin	▪ **ARM A**: pictilisib + paclitaxel ▪ **ARM B**: placebo + paclitaxel
Primary endpoint	▪ Progression-free survival	▪ Progression-free survival	▪ Progression-free survival
Status	▪ Recruitment completed Q1 2014 ▪ Data presented at SABCS 2014	▪ FPI Q1 2012	▪ Recruitment completed Q2 2014

Polatuzumab vedotin (RG7596)

Antibody drug conjugate targeting CD79b for the treatment of B-cell malignancies

Indication	Non-Hodgkin's lymphoma	Non-Hodgkin's lymphoma	Relapsed or Refractory follicular lymphoma and DLBCL
Phase	**Phase II ROMULUS**	**Phase Ib**	**Phase Ib/II**
# of patients	N=120	N=90	N=224
Design	▪ **ARM A:** pinatuzumab vedotin plus Rituxan ▪ **ARM B:** polatuzumab vedotin plus Rituxan ▪ **ARM C:** polatuzumab vedotin plus Gazyva	▪ Dose escalation study in combination with Rituxan and chemotherapy	▪ PIb: dose escalation ▪ P2: polatuzumab vedotin + BR vs. BR ▪ P2 expansion: polatuzumab vedotin +Gazyva non-randomised
Primary endpoint	▪ Safety and anti-tumor activity	▪ Safety	▪ Safety
Status	▪ Recruitment completed Q1 2014 ▪ Pinatuzumab vedotin portion of the study completed ▪ Updated data presented at ASH 2014 ▪ FPI in Gazyva arm expected in Q1 2015	▪ FPI Q4 2013	▪ FPI Q4 2014

In collaboration with Seattle Genetics
ASH=American Society of Hematology; BR=bendamustine and Rituxan

Taselisib (RG7604, GDC-0032)

Mutant-selective PI3 kinase inhibitor targeting commonly mutated oncogene

Indication	HER2-negative ER-positive metastatic breast caner patients who progressed after aromatase inhibitor therapy	Neoadjuvant HER2-negative ER-positive breast cancer
Phase	**Phase III** **SANDPIPER**	**Phase II** **LORELEI**
# of patients	N=600	N=330
Design	▪ **ARM A**: taselisib plus Fulvestrant ▪ **ARM B:** placebo plus Fulvestrant	▪ **ARM A**: taselisib plus letrozole ▪ **ARM B:** placebo plus letozole
Primary endpoint	▪ Progression-free survival	▪ Response rate and pCR
Status	▪ Expect FPI Q1 2015	▪ FPI Q4 2014

Taselisib (RG7604, GDC-0032)

Mutant-selective PI3 kinase inhibitor targeting commonly mutated oncogene

Indicationx	Solid tumors and HER2-negative HR-positive breast cancer	HER2-negative HR-positive locally recurrent or metastatic breast cancer	PI3KCAmut-pos. 2L squamous NSCLC Lung Master Protocol
Phase	**Phase I/II**	**Phase I**	**Phase II Lung-MAP**
# of patients	N=320	N=65	N=120
Design	▪ **Phase I** ▪ taselisib ▪ taselisib plus letrozole or fulvestrant ▪ **Phase II** ▪ taselisib (multiple doses) plus letrozole or fulvestrant	▪ taselisib plus docetaxel ▪ taselisib plus paclitaxel	▪ taselisib vs. chemo
Primary endpoint	▪ Safety/PK/efficacy	▪ Safety	▪ Progression-free survival
Status	▪ Recruitment completed Q2 2014 ▪ Updated data presented at SABCS 2014	▪ FPI Q2 2013	▪ FPI Q2 2014

SABCS=San Antonio Breast Cancer Symposium

Venetoclax (RG7601, ABT-199/GDC-0199)

Novel small molecule Bcl-2 selective inhibitor

Indication	Relapsed or Refractory CLL	Untreated CLL patients with coexisting medical conditions	Relapsed or Refractory CLL with 17p deletion
Phase/study	**Phase III MURANO**	**Phase III CLL14**	**Phase II**
# of patients	N=370	N=432	N=100
Design	▪ **ARM A**: venetoclax plus Rituxan ▪ **ARM B**: Rituxan plus bendamustine	▪ **ARM A**: venetoclax plus Gazyva ▪ **ARM B**: chlorambucil plus Gazyva	▪ Single-agent venetoclax
Primary endpoint	▪ Progression-free survival	▪ Progression-free survival	▪ Safety/MTD
Status	▪ FPI Q1 2014	▪ FPI Q4 2014	▪ Recruitment completed Q2 2014

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute)
CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic Lymphoma
ASCO=American Society of Clinical Oncology

Venetoclax (RG7601, ABT-199/GDC-0199)

Novel small molecule Bcl-2 selective inhibitor

Indication	Relapsed or Refractory CLL	Relapsed CLL and SLL	Relapsed or Refractory or previously untreated CLL	Relapsed or Refractory or previously untreated CLL
Phase/study	**Phase II**	**Phase Ib**	**Phase Ib**	**Phase Ib**
# of patients	N=40	N=50	N=70	N=74
Design	▪ venetoclax after ibrutinib therapy ▪ venetoclax after idelalisib therapy	▪ Dose-escalation study in combination with MabThera/Rituxan	▪ venetoclax in combination with MabThera/Rituxan and bendamustine	▪ venetoclax in combination with Gazyva
Primary endpoint	▪ Overall response rate	▪ Safety/MTD	▪ Safety/MTD	▪ Safety/MTD
Status	▪ FPI Q3 2014	▪ FPI Q3 2012 ▪ Data presented at ASCO 2014	▪ FPI Q2 2013	▪ FPI Q1 2014

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute)
CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic Lymphoma
ASCO=American Society of Clinical Oncology

Venetoclax (RG7601, ABT-199/GDC-0199)

Novel small molecule Bcl-2 selective inhibitor

Indication	Relapsed or Refractory follicular non-Hodgkin's lymphoma	Front-line DLBCL	Relapsed or Refractory NHL	Relapsed or Refractory CLL and NHL
Phase/study	**Phase II**	**Phase I/II**	**Phase I**	**Phase I**
# of patients	N=156	N=230	N=40	N=211
Design	▪ **ARM A:** venetoclax plus Rituxan ▪ **ARM B:** venetoclax plus Rituxan plus bendamustine ▪ **ARM C:** Rituxan plus bendamustine	Dose finding: ▪ **ARM A:** venetoclax+R-CHOP ▪ **ARM B:** venetoclax+G-CHOP Expansion: ▪ venetoclax+R/G-CHOP	▪ Dose escalation of venetoclax in combination with Rituxan and bendamustine	▪ Dose-escalation study
Primary endpoint	▪ Overall response rate	▪ Safety and efficacy	▪ Safety/MTD	▪ Safety/PK/Response rate
Status	▪ FPI Q4 2014	▪ FPI Q2 2014	▪ FPI Q2 2012 ▪ Study resumed Q3 2013	▪ FPI Q2 2011 ▪ Updated CLL, SLL and NHL (DLBCL and FL) data presented at ASCO 2014

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute)

Venetoclax (RG7601, ABT-199/GDC-0199)

Novel small molecule Bcl-2 selective inhibitor

Indication	Relapsed or refractory multiple myeloma		Acute myelogenous leukemia (AML)	
Phase/study	**Phase I**	**Phase I**	**Phase II**	**Phase Ib**
# of patients	N=30	N=30	N=54	N=89
Design	▪ Patients receiving Bortezomib and Dexamethasone as standard therapy: ▪ Dose escalation cohort: venetoclax+bortezomib+dexamethasone ▪ Safety expansion cohort: venetoclax+bortezomib+dexamethasone	▪ Dose escalation cohort ▪ Safety expansion cohort	▪ Dose escalation of venetoclax	▪ venetoclax (dose escalation) +decitabine ▪ venetoclax (dose escalation) +azacitidine
Primary endpoint	▪ Safety/MTD	▪ Safety/MTD	▪ Overall response rate	▪ Safety
Status	▪ FPI Q4 2012	▪ FPI Q4 2012	▪ FPI Q4 2013 ▪ Data presented at ASH 2014	▪ FPI Q4 2014

Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute)

Factor IXa/X bispecific (RG6013, ACE910)

Factor VIII mimetic for treatment of hemophilia A

Indication	Hemophilia A	
Phase/study	**Phase I** Study in Japan	**Phase I/II** Study in Japan
# of patients	N=82	N≈18
Design	▪ Enrolled 64 HVs and 18 patients	▪ Expansion study in patients from phase 1
Primary endpoint	▪ Exploratory efficacy and safety	▪ Exploratory efficacy and safety
Status	▪ Recruitment completed Q2 2014 ▪ Data presented at ASH 2014	▪ FPI Q3 2014

In collaboration with Chugai
ASH=American Society of Hematology

Bitopertin (GlyT-1, RG1678)

A small molecule first-in-class glycin reuptake inhibitor (GRI)

Indication	Obsessive-compulsive disorder
Phase/study	**Phase II** **SKYLYTE**
# of patients	N=99
Design	▪ 16-week treatment period ▪ Background therapy of selective serotonin reuptake inhibitors (SSRI) ▪**ARM A**: bitopertin daily (30 mg) ▪**ARM B**: bitopertin daily (10 mg) ▪**ARM C**: placebo
Primary endpoint	▪ Change in total score on Yale-Brown Obsessive Compulsive Scale
Status	▪ FPI Q4 2012

Gantenerumab (RG1450)

Fully human monoclonal antibody against amyloid-beta

Indication	Prodromal Alzheimer's Disease	Mild Alzheimer's Disease
Phase/study	**Phase II/III** **SCarlet RoAD**	**Phase III** **Marguerite Road**
# of patients	N=799	N=1,000
Design	▪ 104-week subcutaneous treatment period ▪ **ARM A:** gantenerumab (225 mg) ▪ **ARM B:** gantenerumab (105 mg) ▪ **ARM C:** placebo	▪ 104-week subcutaneous treatment period ▪ **ARM A:** gantenerumab ▪ **ARM B:** placebo
Primary endpoint	▪ Change in CDR-SOB at 2 years ▪ Sub-study: change in brain amyloid by PET at 2 years	▪ Change in ADAS-Cog and ADCS-ADL at 2 years (co-primary)
Status	▪ Phase I PET data: Archives of Neurology 2012 Feb;69(2):198-207 ▪ Enrollment completed Q4 2013 ▪ Study discontinued due to futility Q4 2014	▪ FPI Q1 2014

In collaboration with Morphosys
CDR-SOB=Clinical Dementia Rating scale Sum of Boxes

Etrolizumab (RG7413)

A humanized monoclonal antibody against beta 7 integrin

Indication	Ulcerative colitis patients who are TNF naïve		
Phase/study	**Phase III** **HIBISCUS I** Induction study	**Phase III** **HIBISCUS II** Induction study	**Phase III** **GARDENIA** Sustained remission study
# of patients	N=350	N=350	N=720
Design	▪ **ARM A**: etrolizumab 105mg SC q4w + adalimumab placebo ▪ **ARM B**: etrolizumab placebo + adalimumab ▪ **ARM C**: etrolizumab placebo + adalimumab placebo	▪ **ARM A**: etrolizumab 105mg SC q4w + adalimumab placebo ▪ **ARM B**: etrolizumab placebo + adalimumab ▪ **ARM C**: etrolizumab placebo + adalimumab placebo	Time on treatment 54 weeks ▪ **ARM A**: etrolizumab 105mg SC q4w + placebo IV ▪ **ARM B**: placebo SC q4w + adalimumab SC
Primary endpoint	▪ Induction of remission compared with placebo as determined by the Mayo Clinic Score (MCS) at week 10	▪ Induction of remission compared with placebo as determined by the Mayo Clinic Score (MCS) at week 10	▪ Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS) at weeks 10, 30 and 54
Status	▪ FPI Q4 2014	▪ FPI Q4 2014	▪ FPI Q4 2014

Etrolizumab (RG7413)

A humanized monoclonal antibody against beta 7 integrin

Indication	UC patient who are TNF naïve and refractory or intolerant to immunosuppressant and/or corticosteroid treatment	UC patient who are refractory or intolerant of TNF inhibitors
Phase/study	**Phase III** **LAUREL** Maintenance study	**Phase III** **HICKORY** Induction and maintenance study
# of patients	N=350	N=800
Design	Induction phase: ▪ **ARM A:** open label etrolizumab 105mg SC q4w Maintenance study: ▪ **ARM B:** etrolizumab 105mg SC q4w ▪ **ARM C:** placebo	Cohort 1 (open-label): ▪ **ARM A:** etrolizumab induction + placebo maintenance ▪ **ARM B:** etrolizumab induction + maintenance Cohort 2 (blinded): ▪ **ARM A:** etrolizumab induction + maintenance ▪ **ARM B:** placebo induction + maintenance
Primary endpoint	▪ Maintenance of remission (at week 62) among randomized patients in remission at Week 10 as determined by the Mayo Clinic Score (MCS)	▪ Clinical Remission (Mayo Clinic Score, MCS) at Week 14 ▪ Remission maintenance (by MCS, at Week 66) among patients with remission at Week 14
Status	▪ FPI Q3 2014	▪ FPI Q2 2014

UC=ulcerative colitis

Etrolizumab (RG7413)

A humanized monoclonal antibody against beta 7 integrin

Indication	Moderate to severe ulcerative colitis	Moderate to severe ulcerative colitis
Phase/study	**Phase II** **SPRUCE** Open label extension study	**Phase III** **COTTONWOOD** Open label extension study
# of patients	N=116	N=2,600
Design	▪ Patients who were enrolled in EUCALYPTUS study and meet enrollment criteria will receive etrolizumab 105 sc q4w	▪ Patients who were previously enrolled in etrolizumab phase III studies and meet enrollment criteria will receive etrolizumab 105 sc q4w
Primary endpoint	▪ Safety	▪ Long-term efficacy as determined by partial Mayo Clinic Score (pMCS) ▪ Incidence of adverse events
Status	▪ Recruitment completed	▪ FPI Q3 2014

HCV: Danoprevir (RG7227)

IFN-based triple regimen for treatment-naïve patients of Asian origin conducted in China

Indication	Treatment-naïve patients of Asian origin with chronic hepatitis C genotype 1 with or without cirrhosis
Phase/study	**Phase II** **DAPSANG**
# of patients	N=61
Design	▪ **Without cirrhosis:** ▪ **ARM A:** Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 12 weeks ▪ **With compensated cirrhosis:** ▪ **ARM B:** Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 24 weeks
Primary endpoint	▪ Safety:
Status	▪ Recruitment completed Q4 2013 ▪ Study ongoing

In collaboration with Ascletis

Lampalizumab (RG7417)

Antibody fragment to selectively block activation of alternative complement pathway

Indication	Geographic atrophy (GA) secondary to age-related macular degeneration		
Phase/study	**Phase III CHROMA**	**Phase III SPECTRI**	**Phase II**
# of patients	N=936	N=936	N=100
Design	▪ **ARM A:** lampalizumab 10mg q4w ▪ **ARM B:** lampalizumab 10mg q6w ▪ **ARM C:** placebo	▪ **ARM A:** lampalizumab 10mg q4w ▪ **ARM B:** lampalizumab 10mg q6w ▪ **ARM C:** placebo	▪ **ARM A:** lampalizumab 10mg q2w ▪ **ARM B:** lampalizumab 10mg q4w ▪ **ARM C:** placebo
Primary endpoint	▪ Primary: change in GA area ▪ Secondary: change in BCVA and in additional measures of visual function	▪ Primary: change in GA area ▪ Secondary: change in BCVA and in additional measures of visual function	▪ Change in GA area
Status	▪ FPI Q3 2014 ▪ Design presented at EURETINA 2014 ▪ Fast track designation received Q4 2014	▪ FPI Q3 2014 ▪ Design presented at EURETINA 2014 ▪ Fast track designation received Q4 2014	▪ FPI Q4 2014

EURETINA=European Society of Retina Specialists

Lebrikizumab (RG3637)

A humanized monoclonal antibody designed to bind specifically to IL-13

	Severe uncontrolled adult asthma	
Indication	**Adult patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication**	
Phase/study	**Phase III LAVOLTA I**	**Phase III LAVOLTA II**
# of patients	N=1,050	N=1,050
Design	▪ Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up ▪ **ARM A:** lebrikizumab high dose ▪ **ARM B:** lebrikizumab low dose ▪ **ARM C:** placebo ▪ Patients will be tested for periostin level	▪ Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up ▪ **ARM A:** lebrikizumab high dose ▪ **ARM B:** lebrikizumab low dose ▪ **ARM C:** placebo ▪ Patients will be tested for periostin level
Primary endpoint	▪ Rate of asthma exacerbations during the 52-week placebo-controlled period	▪ Rate of asthma exacerbations during the 52-week placebo-controlled period
Status	▪ Enrollment completed Q4 2014 ▪ Expect data in 2016	▪ Enrollment completed Q4 2014 ▪ Expect data in 2016

Lebrikizumab (RG3637)

A humanized monoclonal antibody designed to bind specifically to IL-13

Indication	Adolescent patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication	Idiopathic pulmonary fibrosis
Phase/study	**Phase III ACOUSTICS**	**Phase II RIFF**
# of patients	N=375	N=250
Design	▪ Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks with 52 week double-blind active treatment extension ▪ **ARM A:** lebrikizumab high dose, week 1-104 or week 52-104 ▪ **ARM B:** lebrikizumab low dose, week 1-104 or week 52-104 ▪ **ARM C:** placebo, week 1-52	▪ **ARM A:** lebrikizumab SC q4w ▪ **ARM B:** placebo
Primary endpoint	▪ Rate of asthma exacerbations during the 52-week placebo-controlled period	▪ Progression-free survival
Status	▪ FPI Q3 2013	▪ FPI Q4 2013

SOC=Standard of Care; OCS=Oral Corticosteroids

Lebrikizumab (RG3637)

A humanized monoclonal antibody designed to bind specifically to IL-13

Indication	Adult asthma	Adult asthma mild-to-moderate patients
Phase/study	**Phase II VOCALS**	**Phase III STRETTO**
# of patients	N=225	N=300
Design	▪ **ARM A:** lebrikizumab high dose SC q4w ▪ **ARM B:** lebrikizumab low dose SC q4w ▪ **ARM C:** placebo	▪ **ARM A:** lebrikizumab SC q4w ▪ **ARM B:** placebo ▪ **ARM C:** Montelukast
Primary endpoint	▪ Relative change in OCS dose at week 44	▪ Absolute change in FEV1 at week 12
Status	▪ FPI Q1 2014	▪ FPI Q2 2014

Lebrikizumab (RG3637)

A humanized monoclonal antibody designed to bind specifically to IL-13

Indication	Adult asthma	Moderate-to-severe atopic dermatitis
Phase/study	**Phase II** **CLAVIER** Mechanistic biomarker study	**Phase II**
# of patients	N=120	N=300
Design	▪ **ARM A:** lebrikizumab SC q4w ▪ **ARM B:** placebo	▪ **ARM A:** lebrikizumab dose 1 ▪ **ARM B:** lebrikizumab dose 2 ▪ **ARM C:** lebrikizumab dose 3 ▪ **ARM D:** placebo
Primary endpoint	▪ Relative change in airway inflammation (eosinophils/mm2) at week 12	▪ Percentage of patients achieving a 50% reduction in Eczema Area and Severity Index (EASI) score (EASI-50) from baseline to week 12
Status	▪ FPI Q1 2014	▪ Expect FPI Q1 2015

Ocrelizumab (RG1594)

2nd generation anti-CD20 monoclonal antibody

Indication	Relapsing multiple sclerosis (RMS)		Primary progressive multiple sclerosis (PPMS)
Phase/study	**Phase III OPERA I**	**Phase III OPERA II**	**Phase III ORATORIO**
# of patients	N=800	N=800	N=630
Design	▪ 96-week treatment period: ▪ **ARM A:** Ocrelizumab 2x 300 mg iv followed by 600 mg iv every 24 weeks ▪ **ARM B:** Interferon β-1a	▪ 96-week treatment period: ▪ **ARM A:** Ocrelizumab 2x 300 mg iv followed by 600 mg iv every 24 weeks ▪ **ARM B:** Interferon β-1a	▪ 120-week treatment period: ▪ **ARM A:** Ocrelizumab 2x 300 mg iv every 24 weeks ▪ **ARM B:** Placebo
Primary endpoint	▪ Annualized relapse rate at 96 weeks versus Rebif	▪ Annualized relapse rate at 96 weeks versus Rebif	▪ Sustained disability progression versus placebo by Expanded Disability Status Scale (EDSS)
Status	▪ enrollment completed Q1 2013 ▪ Expect data in 2015	▪ enrollment completed Q1 2013 ▪ Expect data in 2015	▪ enrollment completed Q1 2013 ▪ Expect data in 2015

Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group 2014 results

Diagnostics

Foreign exchange rate information

Oncology development programmes
Small molecules

Molecule	MDM2 (4) antagonist (RG7388)	MDM2 (4) ant. IV prodrug (RG7775)	LSD1 inhibitor (RG6016)	Raf/MEK inhibitor (RG7304, CKI27)
Indication	**Acute myeloid leukemia**	**Advanced cancers including AML**	**Acute Leukemia**	**Solid tumors**
Phase	**Phase I**	**Phase I**	**Phase I**	**Phase I**
# of patients	N=100	N=90	N=30	N=52
Design	▪ Multiple ascending dose-escalation study	Dose-escalation study ▪ **ARM A**: patients with advanced solid tumors ▪ **ARM B:** patients with r/r AML	▪ Multiple ascending dose-escalation study	▪ Dose-escalation to MTD
Primary endpoint	▪ MTD	▪ MTD	▪ MTD	▪ MTD and tumor assessment
Status	▪ FPI Q1 2013 ▪ Data presented at ASH 2014	▪ FPI Q2 2014	▪ FPI Q1 2014	▪ Initiated Q4 2008 ▪ enrollment stopped in Q4 2010
Collaborator			Oryzon Genomics, S.A.	Chugai

ASCO=American Society of Clinical Oncology

Oncology development programmes
Monoclonal antibodies

Molecule	Anti-glypican-3 MAb (RG7686, GC33)	
Indication	**Metastatic liver cancer (hepatocellular carcinoma)**	**2L metastatic liver cancer (hepatocellular carcinoma)**
Phase	**Phase Ib**	**Phase II**
# of patients	N= 40-50	N=185
Design	▪ Study US monotherapy ▪ Study Japan monotherapy ▪ Dose escalation study in combo with SOC	▪ Adaptive design study Double blind randomized 2:1 RG7686 : placebo ▪ Patients are stratified according to the level of GPC-3 expression in tumor
Primary endpoint	▪ Safety and tolerability	▪ Progression-free survival
Status	▪ Recruitment completed Q4 2013 ▪ Dose escalation completed for US and Japan monotherapy and combination therapy studies	▪ Recruitment completed Q1 2013 ▪ Results under internal review
Collaborator	Chugai	

SOC=standard of care

Oncology development programmes
Monoclonal antibodies (continued)

Roche pRED

Molecule	GE-huMAb HER3 (RG7116)			Ang2-VEGF MAb (RG7221)	
Indication	**Solid tumors**	**HER2-low and HER3-positive metastatic breast cancer**	**1L mNSCLC of squamous histology**	**Solid tumors**	**Metastatic colorectal cancer**
Phase	**Phase I**	**Phase I**	**Phase Ib/II**	**Phase I**	**Phase II McCAVE**
# of patients	N=105	N=40	N=53	N≈80	N=140
Design	▪ Multiple ascending dose study with extension cohorts and imaging sub-study ▪ Combination arms with HER1-targeted therapies (erlotinib, cetuximab)	▪ Multiple ascending dose of RG7116 in combination with Perjeta and paclitaxel	▪ RG7116 in combination with carboplatin and paclitaxel	▪ Multiple ascending dose study with extension cohorts in solid tumors to assess the PD effects and platinum-resistant ovarian cancer	▪ **ARM A**: Induction: Avastin+mFOLFOX-6; followed by maintenance: Avastin+5-FU/LV ▪ **ARM B**: Induction: RG7221+mFOLFOX-6; followed by maintenance: RG7221+5-FU/LV
Primary endpoint	▪ Safety, PK	▪ Safety	▪ Safety, ORR	▪ Safety, PK	▪ PFS
Status	▪ FPI Q4 2011 ▪ Initial data presented at ASCO 2013	▪ FPI Q3 2013	▪ FPI Q4 2014	▪ FPI Q4 2012 ▪ Dose escalation data presented at ASCO 2014	▪ FPI Q2 2014

ASCO=American Society of Clinical Oncology

Oncology development programmes
Monoclonal antibodies (continued)

Molecule	CSF-1R huMAb (RG7155)		CEA-IL2v (RG7813)
Indication	**Solid tumors and PVNS**	**Solid tumors**	**Solid tumors**
Phase	**Phase I/II**	**Phase I**	**Phase I**
# of patients	N≈140	N=110	N~110
Design	▪ Multiple ascending dose study +/- paclitaxel with extension cohorts	RG7155 in combination with RG7446 (anti-PDL1) ▪ Part 1: dose escalation ▪ Part 2: expansion	▪ Single and multiple dose escalation study with extension cohorts
Primary endpoint	▪ Safety, PK, PD & preliminary clinical activity	▪ Safety	▪ Safety, PK, PD
Status	▪ FPI Q4 2011 ▪ Biomarker data presented at AACR 2013 and AACR 2014 ▪ Data presented at ASCO 2014	▪ FPI January 2015	▪ FPI Q4 2013

AACR=American Association for Cancer Research; ASCO=American Society of Clinical Oncology

Oncology development programmes
Monoclonal antibodies (continued)

Roche pRED

Molecule	MSLN PEcFP (RG7787)	CEA CD3 T-cell bispecific (TCB) (RG7802)	CD40 iMAb (RG7876) in combination with anti-PDL1 (RG7446)
Indication	**MSLN-positive solid tumors**	**CEA-positive solid tumors**	**Solid tumors**
Phase	**Phase I**	**Phase Ia**	**Phase I**
# of patients	N=133	N=90	N=160
Design	▪ Part A: Single agent dose escalation and extensions ▪ Part B: Combination of RG7787 and gemcitabine/nab-paclitaxel dose escalation and extension	▪ Multiple ascending dose study with extension cohorts and imaging sub-study	▪ Part 1A: sequential administration of RG7876 and RG7446 (anti-PDL1) ▪ Part 1B: concomitant administration of RG7876 and RG7446 (anti-PDL1) ▪ Part 2: multiple doses of concomitant RG7876 and RG7446 (anti-PDL1) ▪ Part 3: study drugs schedule in specific indications per Part 2
Primary endpoint	▪ Safety, PK, PD	▪ Safety, PK/PD, imaging	▪ Safety
Status	▪ FPI Q4 2014	▪ FPI Q4 2014	▪ FPI Q4 2014

AACR=American Association for Cancer Research; ASCO=American Society of Clinical Oncology

Neuroscience development programmes

Roche pRED

Molecule	PDE10A inhibitor (RG7203)	TAAR1 agonist (RG7410)	GABRA5 NAM (RG1662)	mGlu5 PAM (RG7342)
Indication	**Schizophrenia**	**Schizophrenia**	**Down Syndrome**	**Schizophrenia**
Phase	**Phase I**	**Phase I**	**Phase IIB CLEMATIS**	**Phase I**
# of patients	N=26	N= up to 40	N=180	N=93
Design	▪ Multiple dose, double-blind study in schizophrenia patients ▪ **ARM A**: RG7203 plus risperidone ▪ **ARM B**: placebo plus risperidone	▪ Double-blind, randomized, placebo controlled, sequential multiple ascending dose study in HVs	▪ For 26 weeks patients will receive: ▪ **ARM A**: RG1662 120mg twice daily ▪ **ARM B**: RG1662 120mg twice daily ▪ **ARM C**: Placebo	▪ Single ascending dose of RG7342
Primary endpoint	▪ Safety, tolerability, PK	▪ Safety and tolerability in HVs	▪ Cognition and adaptive behavior	▪ Safety, tolerability, PK and food effect
Status	▪ Study completed ▪ Results under internal review	▪ Study completed Q4 2014 ▪ Results under internal review	▪ FPI Q2 2014	▪ Study completed January 2015 ▪ Results under internal review

NAM=Negative allosteric modulator; HV= healthy volunteer

Neuroscience development programmes

Roche pRED

Molecule	V1 receptor antagonist (RG7314)	SMN2 splicing modifier (RG7800)	Basimglurant (mGlu5 NAM, RG7090)
Indication	Autism	Spinal muscular atrophy	Adjunctive Treatment of Major Depressive Disorder
Phase	**Phase II VANILLA**	**Phase Ib MOONFISH**	**Phase II Marigold**
# of patients	N=150	N=48	N=300
Design	▪ Multi-center, randomized, double-blind, placebo-controlled proof-of-concept study in individuals with Autism Spectrum Disorder (ASD)	▪ Randomized, double-blind, 12-week, placebo-controlled multiple dose study in adult and pediatric patients	▪ **ARM A:** basimglurant 0.5 mg ▪ **ARM B:** basimglurant 1.5 mg ▪ **ARM C:** matching placebo
Primary endpoint	▪ Safety and efficacy	▪ Safety and tolerability	▪ Efficacy - Montgomery Asberg Depression Rating Scale
Status	▪ FPI Q3 2013	▪ FPI Q4 2014	▪ Study completed ▪ Data in-house under review ▪ Data presented at ECNP and ACNP 2014
Collaborator		PTC Therapeutics/ SMA Foundation	

ECNP=European College of Neuropsychopharmacology; ACNP=American College of Neuropsychopharmacology

Neuroscience development programmes

Roche pRED

Molecule	Anti-aSynuclein (RG7935, PRX002)		Monoamine oxidase type B (MAO-B) inhibitor (RG1577, EVT-302)	MAb Tau-pS422 (RG7345)
Indication	**Parkinson's disease**		**Alzheimer's Disease**	**Alzheimer's disease**
Phase	**Phase I**	**Phase I**	**Phase IIb MAyflOwer RoAD**	**Phase I**
# of patients	N=40	N=up to 60	N=495	N=48
Design	▪ Double-blind, placebo-controlled, multiple ascending dose study of RG7935 in healthy subjects	▪ Double-blind, placebo-controlled, multiple ascending dose study of RG7935 in patients with Parkinson's disease	▪ 52-week oral treatment ▪ **ARM A:** RG1577 (dose 1) ▪ **ARM B:** RG1577 (dose 2) ▪ **ARM C:** placebo	▪ Randomized, double-blind, placebo-controlled, single ascending dose study of RG7345 in healthy volunteers
Primary endpoint	▪ Safety, tolerability, PK, immunogenicity	▪ Safety and tolerability	▪ Changes in ADAS-Cog at 52 weeks	▪ Safety
Status	▪ FSI Q2 2014	▪ FPI Q3 2014	▪ Recruitment completed Q1 2014	▪ FPI Q4 2014
Collaborator	Prothena		Evotec	

Infectious diseases development programmes

Molecule	TLR7 agonist (RG7795)	LptD antibiotic (RG7929)	NME (RG7689)	DBO Beta lactamase inhibitor (RG6080)
Indication	**Chronic hepatitis B**	**Pseudomonas infections (including MDR strains)**	**Infectious diseases**	**Infectious diseases**
Phase	**Phase I**	**Phase II**	**Phase I**	**Phase I**
# of patients	N=50	N=~50	N=77	N=40
Design	▪ Healthy volunteer study ▪ **ARM A**: Single ascending dose of RG7795 ▪ **ARM B**: Placebo	▪ Patient and HV study	▪ Double-blind, randomized, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study in healthy volunteers	▪ Randomized, double-blind, placebo-controlled, single-ascending dose study in healthy volunteers
Primary endpoint	▪ Safety	▪ Safety, PK/PD	▪ Safety, PK/PD	▪ Safety, PK
Status	▪ LPI Q4 2014	▪ FPI Q4 2013 ▪ QIDP and fast track designation granted Q2 2014	▪ FPI Q4 2014	▪ Study completed
Collaborator		Polyphor		Meiji and Fedora

QIDP=Qualified Infectious Disease Product designation

Metabolic, ophthalmology and immunology development programmes

Molecule	GLP-1/GIP dual agonist (MAR709, RG7697)	Aldosterone synthase inhibitor (RG7641)	Anti-VEGF/Ang2 (RG7716)	NME (RG7625)
Indication	Type 2 diabetes	Metabolic diseases	Wet age-related macular degeneration	Autoimmune diseases
Phase/study	**Phase II**	**Phase I**	**Phase I**	**Phase I**
# of patients	N=105	N=96	N=12	N=16
Design	▪ **ARM A:** RG7697 SC ▪ **AMR B:** Liraglutide ▪ **ARM C:** Placebo	▪ **ARM A:** RG7641 single dose ▪ **ARM B:** Placebo	Patient study ▪ Single ascending and multiple dose of RG7716	▪ Single ascending dose of RG7625 in healthy volunteers
Primary Endpoint	▪ HbA1c	▪ Safety	▪ Safety and PK	▪ Safety, PK, PD
Status	▪ FPI Q3 2014	▪ Recruitment completed Q2 2014	▪ Enrollment completed Q4 2014	▪ FPI Q4 2014
Collaborator	Marcadia Biotech, Inc. acquisition			

Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group 2014 results

Diagnostics

Foreign exchange rate information

Oncology development programmes
Monoclonal antibodies

gRED Genentech Research & Early Development

Molecule	Duligotuzumab (Anti-HER3 EGFR DAF MAb, RG7597)	Anti-OX40 (RG7888, MOXR0916)
Indication	**Locally advanced or metastatic tumors with mutant KRAS**	**Solid tumors**
Phase/study	**Phase I**	**Phase I**
# of patients	N=50	N=400
Design	▪ Dose finding of duligotuzumab plus cobimetinib[1]	▪ RG7888 dose escalation and expansion study
Primary endpoint	▪ Safety	▪ Safety
Status	▪ FPI Q4 2013	▪ FPI Q3 2014

[1]cobimetinib in collaboration with Exelixis

Oncology development programmes
Antibody drug conjugates

gRED Genentech Research & Early Development

	Antibody drug conjugates (ADCs)		
Molecule	**Anti-STEAP1 ADC** (RG7450)	**NME ADC** (RG7882)	**NME ADC** (RG7841)
Indication	**Prostate cancer**	**Pt. resistant ovarian cancer or unresectable pancreatic cancer**	**Refractory solid tumors**
Phase	**Phase I**	**Phase I**	**Phase I**
# of patients	N=93	N=75	N=115
Design	▪ Dose escalation and expansion study	▪ Dose escalation study	▪ Dose escalation study
Primary endpoint	▪ Safety	▪ Safety/PK	▪ Safety
Status	▪ Dose escalation study: enrollment completed Q1 2014 ▪ Expansion study: FPI Q3 2014 ▪ Data presented at ASCO 2013-2014 and AACR 2014	▪ FPI Q2 2014	▪ FPI Q2 2014
Collaborator	Seattle Genetics and Agensys	Seattle Genetics	

ASCO=American Society of Clinical Oncology; AACR=American Association for Cancer Research

Oncology development programmes
Antibody drug conjugates (continued)

Genentech Research & Early Development

	Antibody drug conjugates (ADCs)		
Molecule	**Lifastuzumab vedotin** (anti-NaPi2b ADC, RG7599)		
Indication	**NSCLC and ovarian cancer**	**Platinum-sensitive ovarian cancer and NSCLC**	**Platinum-resistant ovarian cancer**
Phase	**Phase I**	**Phase Ib**	**Phase II HERAEA**
# of patients	N=96	N=54	N=92
Design	▪ Dose escalation study	▪ Dose escalation of RG7599 in combination with carboplatin, with or without Avastin	▪ **ARM A**: RG7599 ▪ **ARM B**: Pegylated liposomal doxorubicin
Primary endpoint	▪ Safety	▪ Safety, PK	▪ Progression-free survival
Status	▪ FPI Q2 2011 ▪ Data presented at ASCO 2014	▪ FPI Q4 2013	▪ FPI Q1 2014
Collaborator	Seattle Genetics		

ASCO=American Society of Clinical Oncology

Oncology development programmes
Small molecules

Genentech Research & Early Development

Molecule	Ipatasertib (AKT inhibitor, GDC-0068, RG7440)		
Indication	**2L castration-resistant prostate cancer**	**1L metastatic gastric or gastroesophageal junction adenocarcinoma**	**1L triple-negative breast cancer**
Phase	**Phase II A.MARTIN**	**Phase II JAGUAR**	**Phase II LOTUS**
# of patients	N=262	N=153	N=120
Design	▪ **ARM A**: ipatasertib (400mg) + abiraterone ▪ **ARM B**: ipatasertib (200mg) + abiraterone ▪ **ARM C**: placebo + abiraterone	▪ **ARM A:** ipatasertib + mFOLFOX6 ▪ **ARM B:** placebo + mFOLFOX6	▪ **ARM A:** ipatasertib + paclitaxel ▪ **ARM B:** placebo + paclitaxel
Primary endpoint	▪ Progression-free survival	▪ Progression-free survival	▪ Progression-free survival
Status	▪ Enrollment completed Q4 2014	▪ Enrollment completed Q4 2014	▪ FPI Q3 2014
Collaborator	Array BioPharma		

mFOLFOX6=modified FOLFOX (Folinic acid, Fluorouracil, Oxaliplatin)

Oncology development programmes
Small molecules (continued)

gRED Genentech Research & Early Development

Molecule	Ipatasertib (AKT inhibitor, GDC-0068, RG7440)	
Indication	**Solid tumors**	**Neoadjuvant TNBC**
Phase	**Phase Ib**	**Phase II FAIRLANE**
# of patients	N=120	N=150
Design	▪ Dose escalation with: ▪ **ARM A:** docetaxel ▪ **ARM B:** fuoropyrimidine plus oxaliplatin ▪ **ARM C:** paclitaxel ▪ **ARM D:** enzalutamide	▪ **ARM A**: ipatasertib + paclitaxel ▪ **ARM B**: placepbo + paclitaxel
Primary endpoint	▪ Safety	▪ Pathalogic Complete Response
Status	▪ FPI Q3 2011 ▪ Data presented at ESMO and SABCS 2014	▪ FPI Q1 2015
Collaborator	Array BioPharma	

ESMO=European Society for Medical Oncology; SABCS=San Antonio Breast Cancer Symposium

Oncology development programmes

Small molecules (continued)

gRED Genentech Research & Early Development

Molecule	Indoleamine 2, 3-dioxygenase (IDO) Inhibitor (GDC-0919, NLG919)	ChK1 inhibitor (RG7741,GDC-0575)	ERK inhibitor (RG7842, GDC-0994)
Indication	**Solid tumors**	**Solid tumors or lymphoma**	**Solid tumors**
Phase	**Phase I**	**Phase I**	**Phase I**
# of patients	N=36	N=170	N=78
Design	▪ Dose escalation and expansion study	▪ Stage 1: Dose escalation ▪ Stage 2: Cohort expansion	▪ Stage 1: Dose escalation ▪ Stage 2: Cohort expansion
Primary endpoint	▪ Safety	▪ Safety/PK	▪ Safety, MTD, PK
Status	▪ FPI Q1 2014	▪ FPI Q2 2012	▪ FPI Q2 2013
Collaborator	NewLink Genetics	Array BioPharma	

Oncology development programmes
Small molecules (continued)

gRED Genentech Research & Early Development

Molecule	Selective estrogen receptor degrader (SERD) (GDC-0810/ARN-810, RG6046)	Selective estrogen receptor degrader (SERD(2)) (GDC-0927/SRN-927, RG6047)
Indication	**Metastatic ER+ HER2- breast cancer**	**Metastatic ER+ HER2- breast cancer**
Phase	**Phase I/IIa**	**Phase I**
# of patients	N=141	N=90
Design	▪ Phase I: dose escalation ▪ Phase IIa: dose expansion	▪ Dose escalation study
Primary endpoint	▪ Safety, PK, MTD	▪ Safety
Status	▪ FPI Q4 2014	▪ FPI Q4 2015
Collaborator	Seragon acquisition	

Neuroscience development programmes

gRED Genentech Research & Early Development

Molecule	**Crenezumab** (RG7412)	
Indication	**Alzheimer's Disease**	
Phase/study	**Phase II** **ABBY** Cognition study	**Phase II** **BLAZE** Biomarker study
# of patients	N=446	N=91
Design	▪ **ARM A**: Crenezumab sc ▪ **ARM B**: Crenezumab iv ▪ **ARM C:** Placebo	▪ **ARM A**: Crenezumab sc ▪ **ARM B**: Crenezumab iv ▪ **ARM C:** Placebo
Primary endpoint	▪ Change in cognition (ADAS-cog) and Clinical Dementia Rating, Sum of Boxes (CDR-SOB) score from baseline to week 73	▪ Change in brain amyloid load from baseline to week 69
Status	▪ enrollment completed Q3 2012 ▪ Positive trend in cognition was observed in ARM B for people with milder disease ▪ Data presented at AAIC 2014	▪ enrollment completed Q3 2012 ▪ Cognition data presented at AAIC 2014 ▪ Exploratory amyloid PET analysis suggests reduced amyloid accumulation in ARM B ▪ Biomarker data presented at CTAD 2014
Collaborator	AC Immune	

AAIC=Alzheimer's Association International Conference; CTAD=Clinical Trials on Alzheimer's Disease

Neuroscience development programmes

gRED Genentech Research & Early Development

Molecule	Crenezumab (RG7412)		Nav1.7 (RG7893, GDC-0276)
Indication	**Mild to Moderate Alzheimer's disease**	**Alzheimer's Prevention Initiative (API) Colombia**	**Pain**
Phase/study	**Phase I**	**Phase II** Cognition study	**Phase I**
# of patients	N=24	N=300	N=74
Design	▪ **ARM A**: crenezumab dose level 1 ▪ **ARM B**: placebo dose level 1 ▪ **ARM C:** crenezumab dose level 2 ▪ **ARM D**: placebo dose level 2	▪ **ARM A**: 100 carriers receive crenezumab sc ▪ **ARM B**: 100 carriers receive placebo ▪ **ARM C:** 100 non-carriers receive placebo	▪ Phase 1, randomized, placebo-controlled, double blinded study to determine safety, tolerability, and pharmacokinetics in healthy volunteers
Primary endpoint	▪ Safety (incidence and nature of MRI safety findings)	▪ Change on Alzheimer's Prevention Initiative (API) Composite Cognitive Test total score	▪ Safety, tolerability, and pharmacokinetics of single and multiple doses
Status	▪ Expect FPI Q1 2015	▪ FPI Q4 2013	▪ FPI Q3 2014
Collaborator	AC Immune	AC Immune and Banner Alzheimer's Institute	Xenon Pharmaceuticals Inc.

Immunology and infectious diseases development programmes

gRED Genentech Research & Early Development

Molecule	NME (RG7880)	Anti-Flu A (RG7745)	
Indication	**Inflammatory diseases**	**Influenza**	
Phase/study	**Phase I**	**Phase IIa**	**Phase IIb**
# of patients	N=74	N=100	N~300
Design	▪ Healthy volunteer study	Healthy volunteers in an influenza challenge model ▪ ARM A: RG7745 ▪ ARM B: placebo ▪ ARM C: Tamiflu	Hospitalized patients requiring oxygen with severe influenza A ▪ ARM A: RG7745 + Tamiflu ▪ ARM B: placebo + Tamiflu
Primary endpoint	▪ Safety and tolerability	▪ Reduction in viral activity	▪ Safety and efficacy (time to normalization of respiratory function)
Status	▪ FPI Q4 2014	▪ Data positive with 98% reduction of viral load at 3600mg dose ▪ Presented at ISIRV 2014	▪ FPI expected Q1 2015

ISIRV=International Society for Influenza and other Respiratory Virus Diseases

Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group 2014 results

Diagnostics

Foreign exchange rate information

2014: One-off items

CHFm	2014				2013			
	Group	**Pharma**	**Dia**	**Corpo-rate**	**Group**	**Pharma**	**Dia**	**Corpo-rate**
Sale of filgrastim rights (2014)	+428	+428						
Op. profit related to filgrastim revenue (2013)					+121	+121		
Past service income (2013)					+302	+131	+67	+104
340B reserves release (2013)					+145	+145		
Core operating profit	**+428**	**+428**			**+568**	**+397**	**+67**	**+104**
Income taxes	-93				-144			
Net income	**+335**				**+424**			

Geographical sales split by divisions and Group*

CHFm	2014	2013	% change CER
Pharmaceuticals Division	**36,696**	**36,304**	**+4**
United States	15,822	15,097	+6
Europe	9,422	9,254	+3
Japan	3,301	3,405	+7
International	8,151	8,548	+2
Diagnostics Division	**10,766**	**10,476**	**+6**
United States	2,401	2,331	+4
Europe	4,131	4,077	+2
Japan	449	492	0
International	3,785	3,576	+13
Group	**47,462**	**46,780**	**+5**
United States	18,223	17,428	+6
Europe	13,553	13,331	+3
Japan	3,750	3,897	+6
International	11,936	12,124	+6

* Geographical sales split shown here does not represent operational organization; CER=Constant Exchange Rates

Pharma Division sales 2014 (vs. 2013)

Top 20 products

	Global		US		Europe		Japan		International	
	CHFm	% CER	CHFm	% CER	CHFm	% CER	CHFm	% CER	CHFm	% CER
MabThera/Rituxan	6,900	2	3,334	1	2,014	6	226	0	1,326	-1
Avastin	6,417	6	2,682	6	1,958	3	711	9	1,066	12
Herceptin	6,275	7	1,967	12	2,234	3	270	1	1,804	8
Lucentis	1,701	2	1,701	2	-	-	-	-	-	-
Tarceva	1,292	-1	641	7	303	-11	99	10	249	-10
Actemra/RoActemra	1,224	23	406	31	433	22	214	19	171	14
Pegasys	1,015	-20	194	-36	236	-33	60	28	525	-8
Xolair	975	25	975	25	-	-	-	-	-	-
Tamiflu	959	54	686	62	74	292	113	18	86	7
Perjeta	918	189	540	150	238	253	79	281	61	326
CellCept	811	-4	195	-3	216	-8	57	-9	343	-1
Xeloda	776	-46	185	-70	92	-70	90	-8	409	-9
Activase/TNKase	747	11	698	11	-	-	-	-	49	13
Valcyte/Cymevene	726	7	386	9	182	6	-	-	158	5
Pulmozyme	597	7	386	10	122	-1	0	-	89	5
Kadcyla	536	135	282	29	176	*	35	-	43	*
NeoRec./Epogin	460	-8	-	-	189	-12	57	-37	214	12
Mircera	417	5	-	-	101	-1	195	0	121	18
Zelboraf	301	-12	69	-44	188	-3	-	-	44	41
Madopar	292	-3	-	-	106	-4	17	-3	169	-1

CER=Constant Exchange Rates
* over +500%

Pharma Division sales 2014 (vs. 2013)

Recently launched products

	Global		US		Europe		Japan		International	
	CHFm	% CER	CHFm	% CER	CHFm	% CER	CHFm	% CER	CHFm	% CER
Erivedge	128	75	83	27	39	399	-	-	6	*
Gazyva	49	*	43	*	5	-	-	-	1	-
Esbriet	44	-	5	-	36	-	-	-	3	-

CER=Constant Exchange Rates
* over +500%

Pharma Division CER sales growth[1] in %

Global top 20 products

	Q4/13	Q1/14	Q2/14	Q3/14	Q4/14
MabThera/Rituxan	7	3	5	1	-1
Avastin	13	9	4	6	7
Herceptin	7	3	9	9	7
Lucentis	22	8	4	2	-5
Tarceva	4	-5	3	0	-2
Actemra/RoActemra	23	23	21	28	20
Pegasys	-20	-19	-10	-22	-29
Xolair	17	15	22	33	29
Tamiflu	-27	9	-36	121	129
Perjeta	394	274	277	227	103
CellCept	-10	-1	-11	0	-4
Xeloda	-3	-19	-50	-61	-56
Activase/TNKase	19	-1	26	19	5
Valcyte/Cymevene	26	12	12	19	-9
Pulmozyme	18	3	8	13	4
Kadcyla	-	474	105	103	110
NeoRec./Epogin	-14	-9	-8	-12	-1
Mircera	23	21	2	-1	0
Zelboraf	26	-2	-9	-13	-24
Madopar	9	-20	3	-6	13

CER=Constant Exchange Rates
[1] Q4/13 vs. Q4/12; Q1-Q4/14 vs. Q1-Q4/13

Pharma Division CER sales growth[1] in %

Top 20 products by region

	US				Europe				Japan				International			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
MabThera/Rituxan	-2	8	-4	5	6	8	4	7	20	-17	5	-4	12	-2	9	-17
Avastin	6	6	3	7	8	2	1	3	27	-5	13	5	7	9	15	16
Herceptin	4	17	10	17	2	4	4	2	23	-12	5	-7	0	12	14	6
Lucentis	8	4	2	-5	-	-	-	-	-	-	-	-	-	-	-	-
Tarceva	-6	16	11	9	-12	-12	-9	-9	42	6	7	-6	-6	-9	-13	-13
Actemra/RoActemra	22	30	39	31	20	20	25	22	49	5	21	11	3	28	21	6
Pegasys	-40	-14	-51	-49	-19	-32	-38	-46	16	45	48	-1	-7	3	-8	-17
Xolair	15	22	33	29	-	-	-	-	-	-	-	-	-	-	-	-
Tamiflu	-9	22	155	127	*	-71	49	-93	-17	-74	238	190	-8	-44	37	350
Perjeta	161	205	202	86	*	287	228	171	-	-	375	32	*	*	341	177
CellCept	-7	-6	16	-18	-10	-5	-6	-11	5	-14	-12	-13	6	-16	-3	13
Xeloda	-15	-80	-93	-92	-57	-71	-76	-77	8	-23	-6	-8	-3	-2	-19	-10
Activase/TNKase	0	27	18	4	-	-	-	-	-	-	-	-	-4	19	27	12
Valcyte/Cymevene	26	8	21	-13	5	10	22	-9	-	-	-	-	-7	24	12	-1
Pulmozyme	2	10	20	9	2	-1	-5	-2	-	-	-	-	10	9	10	-1
Kadcyla	315	16	3	-7	-	*	*	*	-	-	-	-	-	*	*	*
NeoRec./Epogin	-	-	-	-	-14	-10	-15	-10	-26	-45	-38	-39	7	12	3	28
Mircera	-	-	-	-	8	-1	-3	-8	36	-12	-2	-11	8	32	1	30
Zelboraf	-40	-46	-38	-51	12	8	-12	-16	-	-	-	-	98	56	65	-1
Madopar	-	-	-	-	-9	-2	-5	-2	4	-6	-2	-5	-29	7	-7	24

CER=Constant Exchange Rates

* over 500%

[1] Q1-Q4/14 vs. Q1-Q4/13

CER sales growth (%)
Quarterly development

	2013 vs. 2012				2014 vs. 2013			
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Pharmaceuticals Division	**7**	**4**	**9**	**7**	**4**	**4**	**4**	**5**
United States	13	7	16	5	3	8	4	10
Europe	1	2	3	2	5	1	1	4
Japan	2	2	4	2	19	-4	8	5
International	8	2	5	18	1	3	6	0
Diagnostics Division	**1**	**4**	**7**	**5**	**7**	**5**	**7**	**7**
Roche Group	**6**	**4**	**8**	**7**	**5**	**4**	**5**	**6**

CER=Constant Exchange Rates

2014: Oncology franchise



2014 sales of CHF 22.797bn

US

- HER2 franchise (including strong uptake of PERJETA & Kadcyla), and Avastin (+6%) driving growth and performance

Europe

- Growth mainly driven by HER2 franchise (with strong uptake of PERJETA & Kadcyla), as well as MabThera (+6%)

International

- Continued strong growth for Avastin (+12%) and Herceptin (+8%)

Japan

- Growth driven largely by Avastin (+9%)

CER=Constant Exchange Rates

MabThera/Rituxan

Global sales



Regional sales



2014 sales of CHF 6.900bn

- Europe: Growth driven by increased market share in follicular lymphoma, as well as CLL (1L)
- US: Sales stable but comparison distorted by 340B baseline effect (+5% excl. base effect)
- International: Growth impacted by economic conditions in Russia but demand remained strong in Latin America

CER=Constant Exchange Rates

Avastin

Global sales



Regional sales



2014 sales of CHF 6.417bn

- Europe: Growth driven by further uptake in ovarian and strong demand across other indications
- US: Sales driven by growing demand in colorectal, cervical and ovarian cancer
- Japan: Driven by higher sales in breast cancer, as well as ovarian cancer and malignant glioma
- International: Strong growth driven by launches in a number of markets for ovarian cancer treatment, as well as by demand in colorectal cancer

CER=Constant Exchange Rates

HER2 Franchise (Herceptin, Perjeta, Kadcyla)

Global sales



Regional sales



2014 sales of CHF 7.729bn

- Strong growth driven by continued uptake of PERJETA in 1/2L mBC and in the neoadjuvant setting, (particularly US), as well as by Kadcyla in 2L mBC
- Continued strong growth in Herceptin benefiting from higher volumes / prolonged treatment times

CER=Constant Exchange Rates

Herceptin

Global sales



Regional sales



2014 sales of CHF 6.275bn

- US: Continued growth in mBC (1L)
- Europe: Strong demand in Germany; subcutaneous formulation now available in many markets
- Japan: Increased usage in combination with PERJETA
- International: Strong growth in Latin America driven by access in public markets, as well as Asia, particularly from the patient assistance program in China

CER=Constant Exchange Rates

Perjeta





2014 sales of CHF 0.918bn

- Perjeta sales grew in all regions with strong uptake in the US, Germany and France
  - Approved in all major markets for 1L mBC (US, EU, Japan and most E7)
  - Neoadjuvant Indication approved in several markets
  - Also benefitting from impressive OS results of CLEOPATRA study

CER=Constant Exchange Rates

Xeloda

Global sales



Regional sales



2014 sales of CHF 0.776bn

- Overall impact due to loss of exclusivity (LoE):
  - US: LoE in February 2014
  - Europe: LoE in December 2013

CER=Constant Exchange Rates

Tarceva

Global sales



Regional sales



2014 sales of CHF 1.292bn

- Europe: Increased demand in 1L EGFR Mut+ market offset by decline 2L EGFR WT NSCLC
- Japan: Good growth following launch of 1L Mut+ NSCLC indication in Q3 2014
- International: Local competition in China

CER=Constant Exchange Rates

2014: Immunology franchise



2014 sales of CHF 5.087bn

- Overall strong demand for immunology medicines, notably in treatment of rheumatoid arthritis (RA) with Actemra (+23%) and Xolair (+25%) for chronic hives and allergic asthma

Actemra/RoActemra

- US, EU & Japan: Strong growth driven by increased use in monotherapy and earlier use for RA, with significant uptake of new SC formulation. EU approval for early-stage RA
- International: Growth driven by strong launches in China & Turkey, and continued fast uptake in Australia & Argentina

Xolair

- Approved by FDA to treat a form of chronic hives in 2014, adding to its use in allergic asthma

CER=Constant Exchange Rates

Tamiflu quarterly sales 2010 – 2014

Retail and Governments/Corporations



Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group 2014 results

Diagnostics

Foreign exchange rate information

Diagnostics Division CER growth
By Region and Business Area (vs. 2013)

	Global		North America		EMEA[1]		RoW	
	CHFm	% CER growth	CHFm	% CER growth	CHFm	% CER growth	CHFm	% CER growth
Professional Diagnostics	6,045	8	1,236	6	2,585	4	2,224	15
Diabetes Care	2,392	1	442	-6	1,475	2	475	6
Molecular Diagnostics	1,613	6	579	10	628	4	406	3
Tissue Diagnostics	716	10	415	6	198	17	103	20
Diagnostics Division	**10,766**	**6**	**2,672**	**4**	**4,886**	**4**	**3,208**	**12**

CER=Constant Exchange Rates
[1] Europe, Middle East and Africa

Diagnostics Division quarterly sales and CER growth[1]

	Q3 13		Q4 13		Q1 14		Q2 14		Q3 14		Q4 14	
	CHFm	% CER	CHFm	% CER	CHFm	% CER	CHFm	% CER	CHFm	% CER	CHFm	% CER
Professional Diagnostics	1,426	9	1,521	10	1,392	9	1,512	8	1,493	8	1,648	8
Diabetes Care	576	3	678	-4	538	5	602	-4	581	4	671	1
Molecular Diagnostics	383	4	416	3	370	4	392	3	403	8	448	7
Tissue Diagnostics	159	8	184	10	156	4	178	14	175	13	207	10
Dia Division	**2,544**	**7**	**2,799**	**5**	**2,456**	**7**	**2,684**	**5**	**2,652**	**7**	**2,974**	**7**

CER=Constant Exchange Rates
[1] versus same period of prior year

2014: Diagnostics Division sales
Growth driven by Asia Pacific

CHF 10,766 m



CER sales growth



CER=Constant Exchange Rates
[1] Europe, Middle East and Africa

2014: Diagnostics Division sales
Growth driven by Professional Diagnostics

CHF 10,766 m



CER sales growth



CER=Constant Exchange Rates

Professional Diagnostics

Strong growth driven by Immunodiagnostics



CER=Constant Exchange Rates

Diabetes Care

Adapting to a challenging market environment



CER=Constant Exchange Rates

Molecular Diagnostics
Growth driven by Virology



CER=Constant Exchange Rates

Tissue Diagnostics

Strong growth in EMEA[1] and North America



CER=Constant Exchange Rates
[1] Europe, Middle East and Africa

2015: Key planned product launches
Professional Diagnostics

Product	Description	Region
cobas c 513	dedicated HbA1C analyzer	EU
cobas t 411	core lab coagulation analyzer	EU
Cobas 8100 V2	integrated pre- and post-analytical solution	WW
CoaguChek Pro II	professional system for PT and aPTT testing	EU
HTLV	human T-lymphotropic virus diagnostics test	EU
Cobas h 232 Troponin T	Point of Care test version of Elecsys cTNT-hs	EU

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors

2015: Key planned product launches
Molecular Diagnostics

Product	Description	Region
cobas® 6800/8800	medium to high volume automated real-time PCR	US
cobas® 6800/8800 MPX	multiplex bloodscreening test	US
cobas® 6800/8800 HBV	quantitative HBV viral load test	EU
cobas® 4800 HIV-1 cobas® 4800 HCV cobas® 4800 HBV	quantitative HIV viral load test quantitative HCV viral load test quantitative HBV viral load test	EU
cobas® EGFR Test v2	detection of EGFR in plasma	EU
cobas® Liat Influenza A/B + RSV	POC detection	US

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors

2015: Key planned product launches
Tissue Diagnostics

Product	Description	Region
VENTANA HE 600	automated H&E staining platform	WW

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors

2015: Key planned product launches
Diabetes Care

Product	Description	Region
Accu-Chek Active no-code	next-gen. bG meter, no coding of test strips	WW
Accu-Chek Connect	bG meter with connectivity to smartphones, mobile applications and cloud	US

Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors

Pipeline summary

Marketed products additional indications

Global Development late-stage trials

pRED (Roche Pharma Research & Early Development)

gRED (Genentech Research & Early Development)

Roche Group 2014 results

Diagnostics

Foreign exchange rate information

CHF / USD


Monthly averages
0,99
0,97
0,95
0,93
0,91
0,89
0,87
2013
2014
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec


Year-To-Date averages
0,99
0,97
0,95
0,93
0,91
0,89
0,87
2013
2014
-4%
-5%
-4%
-1%
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

CHF / USD


0.99
0.97
0.95
0.93
0.91
0.89
0.87
monthly avg 2013
avg full year 2013
-1%
avg full year 2014
monthly avg 2014
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

CHF / EUR


Monthly averages
1,25
1,24
1,23
1,22
1,21
1,20
2013
2014
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec


Year-To-Date averages
1,25
1,24
1,23
1,22
1,21
1,20
2013
2014
0%
-1%
-1%
-1%
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

CHF / EUR


1.25
1.24
1.23
1.22
1.21
1.20
monthly avg 2013
avg full year 2013
-1%
avg full year 2014
monthly avg 2014
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec

Average exchange rates

	YTD Dec 14	YTD Dec 13
USD	0.91	0.93
EUR	1.21	1.23
JPY	0.86	0.95

YTD Dec 14 vs. YTD Dec 13



Exchange rate impact on sales growth

In 2014 negative impact from Latin American currencies, JPY and USD

Development of average exchange rates versus prior year period

CHF / EUR	-0.4%	-0.7%	-1.1%	-1.3%
CHF / USD	-4.0%	-4.8%	-3.9%	-1.3%
CHF / JPY	-13.9%	-11.4%	-9.8%	-9.0%
Difference in CHF / CER growth	-5.8%p	-5.9%p	-4.9%p	-3.4%p



CER=Constant Exchange Rates

Exchange rate impact on sales growth

In 2014 negative impact from Latin American currencies, JPY and USD

Development of average exchange rates versus prior year period

CHF / EUR	-0.4%	-0.9%	-1.9%	-2.0%
CHF / USD	-4.0%	-5.6%	-1.9%	+6.7%
CHF / JPY	-13.9%	-8.9%	-6.6%	-6.3%
Difference in CHF / CER growth	-5.8%p	-5.9%p	-3.0%p	+1.0%p



CER=Constant Exchange Rates

Exchange rate impact on sales growth

Negative impact from Latin American currencies, JPY and USD



CER=Constant Exchange Rates

Doing now what patients need next